- Home
- GENK vs IGC Comparison
GENK vs IGC Comparison
Compare GENK & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GENK | IGC |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0M | 28.5M |
| IPO Year | 2023 | 2005 |
Fundamental Metrics
Financial Performance| Metric | GENK | IGC |
|---|---|---|
| Price | $2.05 | $0.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $5.67 | $5.00 |
| AVG Volume (30 Days) | 39.2K | ★ 289.3K |
| Earning Date | 05-12-2026 | 03-19-2026 |
| Dividend Yield | ★ 1.64% | N/A |
| EPS Growth | ★ 62.50 | 59.09 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $208,380,000.00 | $1,271,000.00 |
| Revenue This Year | $8.46 | $3.54 |
| Revenue Next Year | $8.17 | $15.12 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.12 | N/A |
| 52 Week Low | $1.50 | $0.24 |
| 52 Week High | $6.18 | $0.50 |
Technical Indicators
Market Signals| Indicator | GENK | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 63.67 | 39.64 |
| Support Level | $1.58 | N/A |
| Resistance Level | $2.55 | $0.31 |
| Average True Range (ATR) | 0.19 | 0.02 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 84.94 | 9.42 |
Price Performance
Historical ComparisonAbout GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.